(R) -Lansoprazole Dexlansoprazole CAS 138530-94-6 Intende 98.0~ 102.0% (HPLC)
Ruifu Chemical Supple Lansoprazole Intermedia
Lansoprazole CAS 103577-45-3
Lansoprazole Chloride Compone CAS 127337-60-4
(R) -Lansoprazole Dexlansoprazole CAS 138530-94-6
Nomen chemicum | (R) -Lansoprazole |
Synonyma | R-(+)-Lansoprazole;Dexlansoprazole;2-[(R)-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole;T 168390;TAK 390;Lansoprazole De immunditia 14;Dexlansoprazole Related Impurities 2;(R) -2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-Benzimidazole; |
CAS Number | 138530-94-6 |
CATTUS Number | RF-PI1916 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C16H14F3N3O2S |
M. Pondus | 369.36 |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Alba ad Off-White Crystalline pulveris |
Solubilitas | Solutum in Dimethylformamide, prope Insolubile in Aqua |
Claritas & Color solutionis | Meets opus est |
Lepidium sativum IR | Imaginum effusio ultrarubrum congruere debet cum substantia referente |
Lepidium sativum HPLC | Retentionis tempus praecipuum cacumen debet consentaneum esse cum illo referendi |
Imprimis Rotationes | +142.0°~+149.0° |
Liquescens punctum | ~140.0℃ |
Aqua Content (KF) | <1.00% |
Residere in Ignition | <0.10% |
Related immunditias | (HPLC) |
Nitrogen Oxides | <0.10% |
Sulfone | <0.40% |
Sulfide | <0.20% |
Alia alia immunditia | <0.10% |
Totalis immunditias | <0.60% |
Puritas optica (HPLC) | >99.5% |
Assay | 98.0~ 102.0% (HPLC, %w/w, in fundamento anhydroso, libero solvendo) |
Metalla gravis | <10ppm |
RELICTUM Solvents | |
Toluene | <890ppm |
n-Heptane | <5000ppm |
Bacterial Endotoxin | <2.5EU/mg |
Test Standard | USP Latin;Pharmacopoeia Sinica |
Consuetudinem | API;Oraliter Active Proton Pump Inhibitor |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore
(R)-Lansoprazole (CAS: 138530-94-6) est R enantiomer de Lansoprazole, Lansoprazole (AG 1749) ore activo protono inhibitor sentinae, quae prohibet stomachum ne acidum gignat.Dexlansoprazole pro Lansoprazole dextroisomer, est quaedam pharmaca anti peptici ulceris pro derivatis benzimidazolis substitutis, in structura hypothetica in elementum fluorinum, secundum sentinam protonom inhibitores omeprazole post.Dexlansoprazole effectum habet inhibitionis secretionis acidi gastrici, melior effectus quam aliorum medicamentorum (Omeprazole, Pantoprazole, Rebela, Tetrazolium) eventum ulceris significanter inhibere potest.Praestat famotidine vel Omeprazole ob damnum alcoholis inductum mucosae gastrici et ulceris duodeni maxime ex hypersecretione acidorum causatorum.Praeterea productum eundem effectum pylori anti Helicobacteri cum praeparatione bismuthi habet et pro refluxu esophagitis et Zhuo AI syndrome adhibetur.Takeda pharmaceutica approbationem dexlansoprazoli accepit, dualis emissio formula (R) -isomer lansoprazol protonis sentinae inhibitoris (PPI) iam in foro, ex FDA mense Ianuario 2009. Dexlansoprazole est capsula relaxationis morae pro curationi semel, oralis curationis. cordis aestus cum refluxu gastroesophagico symptomatico non-erosivo (GERD), sanatio esophagitis erosive (EE) et conservatione sanatae EE.